ANCA-associated vasculitis

anca-vasculitis · society: ACR/VF

← back to Rheumatology

Summary

First ACR/Vasculitis Foundation guideline for management of ANCA-associated vasculitis (GPA, MPA, EGPA), providing 26 recommendations + 5 position statements for GPA/MPA and 15 recommendations + 5 position statements for EGPA. Key themes: rituximab preferred over cyclophosphamide for remission induction and maintenance in severe GPA/MPA, mepolizumab introduced for non-severe EGPA, reduced-dose glucocorticoid regimens favored, and routine plasma exchange not recommended. All recommendations are conditional due to limited high-quality evidence. Avacopan was not considered (post-search FDA approval).

Current guideline: ACR/VF 2021 ANCA-Associated Vasculitis Guideline · download Anki sub-deck

Versions

• 2021 · ACR/VF — ACR/VF 2021 ANCA-Associated Vasculitis Guideline
  • Read the guideline: html · pmc · Anki deck

---

Table of contents

• 2021 · ACR/VF